Cargando…

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor

RATIONALE: Schizophrenia is a complex neuropsychiatric disorder characterized, in part, by impaired dopamine signaling. TAK-063 is a selective inhibitor of phosphodiesterase 10A, a key regulator of intracellular signaling pathways that is highly expressed in the striatum. OBJECTIVE: Safety, tolerabi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Max, Chrones, Lambros, Xie, Jinhui, Gevorkyan, Hakop, Macek, Thomas A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063900/ https://www.ncbi.nlm.nih.gov/pubmed/27572830 http://dx.doi.org/10.1007/s00213-016-4412-9

Ejemplares similares

A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events
por: Goldsmith, Paul, et al.
Publicado: (2017)

Translational Development Strategies for TAK-063, a Phosphodiesterase 10A Inhibitor
por: Macek, Thomas A, et al.
Publicado: (2020)

A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects
por: Yurgelun-Todd, Deborah A., et al.
Publicado: (2019)

Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor
por: Harada, Akina, et al.
Publicado: (2015)

Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects
por: Yin, Wei, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK‐648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction
por: Plock, N, et al.
Publicado: (2017)

S223. COMBINED TREATMENT WITH A SELECTIVE PDE10A INHIBITOR TAK-063 AND ANTIPSYCHOTICS AT SUBEFFECTIVE DOSES PRODUCES POTENT ANTIPSYCHOTIC-LIKE EFFECTS WITHOUT EXACERBATING SIDE EFFECTS PROFILE IN RODENTS
por: Suzuki, Kazunori, et al.
Publicado: (2018)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
por: Fedyk, Eric R., et al.
Publicado: (2020)

Combined treatment with a selective PDE10A inhibitor TAK‐063 and either haloperidol or olanzapine at subeffective doses produces potent antipsychotic‐like effects without affecting plasma prolactin levels and cataleptic responses in rodents
por: Suzuki, Kazunori, et al.
Publicado: (2017)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
por: Sakurai, Yuuichi, et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of cyclopropylfentanyl in male rats
por: Bergh, Marianne Skov-Skov, et al.
Publicado: (2021)

Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers
por: Family, Neiloufar, et al.
Publicado: (2019)

Safety, pharmacokinetics and pharmacodynamics of TAK‐418, a novel inhibitor of the epigenetic modulator lysine‐specific demethylase 1A
por: Yin, Wei, et al.
Publicado: (2021)

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
por: Jenkins, H, et al.
Publicado: (2015)

Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting
por: Perea, José Ramón Azanza, et al.
Publicado: (2022)

Activation of PDE10 and PDE11
por: Jäger, Ronald, et al.
Publicado: (2011)

Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects
por: Watanabe, Mai, et al.
Publicado: (2020)

Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin
por: Ruczyński, Jarosław, et al.
Publicado: (2019)

A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobacco-free oral nicotine pouches relative to cigarettes
por: Chapman, Fiona, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
por: Bilal, Muhammad, et al.
Publicado: (2021)

Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia
por: Ahmed, Amir I. A., et al.
Publicado: (2015)

Pharmacodynamic and pharmacokinetic assessment of electronic cigarettes, combustible cigarettes, and nicotine gum: implications for abuse liability
por: Stiles, Mitchell F., et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
por: Peterschmitt, M. Judith, et al.
Publicado: (2020)

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
por: Jacobsen, Paula L., et al.
Publicado: (2015)

Pharmacokinetics and pharmacodynamics of the cytolytic anti‐CD38 human monoclonal antibody TAK‐079 in monkey – model assisted preparation for the first in human trial
por: Roepcke, Stefan, et al.
Publicado: (2018)

P063 Optogenetics for Obstructive Sleep Apnea
por: Knapman, F, et al.
Publicado: (2021)

Publisher Correction: Transportan 10 improves the pharmacokinetics and pharmacodynamics of vancomycin
por: Ruczyński, Jarosław, et al.
Publicado: (2019)

A commonly occurring genetic variant within the NPLOC4–TSPAN10–PDE6G gene cluster is associated with the risk of strabismus
por: Plotnikov, Denis, et al.
Publicado: (2019)

A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia
por: Yin, Wei, et al.
Publicado: (2022)

The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
por: Baldwin, David S, et al.
Publicado: (2016)

Reduction of falls in a rat model of PD falls by the M1 PAM TAK-071
por: Kucinski, Aaron, et al.
Publicado: (2021)

A Population Pharmacokinetic and Pharmacodynamic Analysis of Peginesatide in Patients with Chronic Kidney Disease on Dialysis
por: Naik, Himanshu, et al.
Publicado: (2013)

Pharmacokinetics and Pharmacodynamics of Posaconazole
por: Chen, Lu, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Tedizolid
por: Iqbal, Khalid, et al.
Publicado: (2022)

Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults
por: Katzman, Martin A., et al.
Publicado: (2020)

Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability
por: Usach, Iris, et al.
Publicado: (2013)

O063. Moyamoya disease and headache: case report
por: Tozzi, Elisabetta, et al.
Publicado: (2015)

The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus
por: Dudkowski, Caroline, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s3j5gtobj7pcvdsssvd3tb63je